BioNTech SE (BNTX) Reports Q3 EPS of EUR12.35

BioNTech SE (NASDAQ: BNTX) reported Q3 EPS of EUR12.35, versus (EUR0.88) reported last year. Revenue for the quarter came in at EUR6.09 billion, versus EUR67.5 million reported last year.

Guidance:

Estimated BioNTech COMIRNATY/COVID-19 vaccine revenues for the full 2021 financial year based on up to 2.5 billion doses: ~€16 billion to €17 billion2

For earnings history and earnings-related data on BioNTech SE (BNTX) click here.

You May Also Be Interested In

• Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance
• Marti Technologies (MRT) Misses Q2 EPS by 9c ; Offers Guidance
• Ross Stores (ROST) Tops Q2 EPS by 72c, Beats on Revenue